BioWorld Asia

March 23, 2011

Genfit, Sanofi-Aventis Ink $54M Deal for Metabolic Disorders

Extending a partnership that dates back to 1999, Genfit, of Lille, France, has inked an agreement with Sanofi-Aventis SA, of Paris, to pursue therapies for the treatment of metabolic disorders. (BioWorld International) Read More

Scotland Aims to Double its Life Sciences Sector by 2020

Agennix Finishes Recruitment for NSCLC Drug's Phase III

Ion Channel on Sperm Could Be Key to New Contraceptives

Transgene Sets Game Plan for Cancer Vaccine Post-Roche Exit

Amgen's BioVex Buy Prompts PsiOxus to Expand its Program

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 18, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Maintenance, man: Lilly’s phase III weight trial hits goals

BioWorld

Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...

Insilico CEO Alex Zhavoronkov and the automated lab’s humanoid that runs all preclinical tests in the Hong Kong lab.

AI drug developer Insilico to raise $292 million in Hong Kong IPO

BioWorld

Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...